PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34803706-8	2021	Lorcaserin did not change insulin synthesis ATP content, but lorcaserin decrease cytosolic free calcium level ((Ca2+)i) in MIN6 cells stimulated with glucose and also inhibit insulin secretion and (Ca2+)i in MIN6 treated with potassium chloride.	lorcaserin	61-71	insulin	Homo sapiens	175-182
34803706-1	2021	Lorcaserin is a serotonergic agonist specific to the 5-hydroxytryptamine 2c receptor (5-HT2CR) that is FDA approved for the long-term management of obesity with or without at least one weight-related comorbidity.	lorcaserin	0-10	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	53-84
34803706-12	2021	These results highlight a novel signaling mechanism of lorcaserin and provide valuable insights into the further investigation of 5-HT2CR functions in beta-cell biology and it also provides guidance for the clinical application of lorcaserin.	lorcaserin	55-65	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	130-137
34803706-1	2021	Lorcaserin is a serotonergic agonist specific to the 5-hydroxytryptamine 2c receptor (5-HT2CR) that is FDA approved for the long-term management of obesity with or without at least one weight-related comorbidity.	lorcaserin	0-10	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	86-93
33418204-4	2021	The purpose of this trial was to determine if lorcaserin, a 5HT2c agonist, improves outpatient XR-NTX induction rates.	lorcaserin	46-56	5-hydroxytryptamine receptor 2C	Homo sapiens	60-65
34803706-2	2021	Lorcaserin can restrain patients" appetite and improve insulin sensitivity and hyperinsulinemia mainly through activating 5-HT2CR in the hypothalamus.	lorcaserin	0-10	insulin	Homo sapiens	55-62
34803706-2	2021	Lorcaserin can restrain patients" appetite and improve insulin sensitivity and hyperinsulinemia mainly through activating 5-HT2CR in the hypothalamus.	lorcaserin	0-10	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	122-129
34803706-6	2021	Dose-dependent activation of 5-HT2CR by lorcaserin suppressed GSIS and SB242084 or knockdown of 5-HT2CR abolished lorcaserin"s effect in vitro.	lorcaserin	40-50	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	29-36
34803706-6	2021	Dose-dependent activation of 5-HT2CR by lorcaserin suppressed GSIS and SB242084 or knockdown of 5-HT2CR abolished lorcaserin"s effect in vitro.	lorcaserin	114-124	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	96-103
34803706-8	2021	Lorcaserin did not change insulin synthesis ATP content, but lorcaserin decrease cytosolic free calcium level ((Ca2+)i) in MIN6 cells stimulated with glucose and also inhibit insulin secretion and (Ca2+)i in MIN6 treated with potassium chloride.	lorcaserin	0-10	insulin	Homo sapiens	175-182
35599337-6	2022	We propose to test the hypothesis in a diet-induced obesity (DIO) rat model by treating animals with the 5-HT2C agonist lorcaserin and the H1 agonist and H3 antagonist betahistine.	lorcaserin	120-130	5-hydroxytryptamine receptor 2C	Rattus norvegicus	105-111
34031163-6	2021	Thus, our results prove the concept that inhibition of 5-HT2CR desensitization can be a valid strategy to improve the long-term weight loss effects of lorcaserin or other 5-HT2CR agonists, and also provide an intellectual framework to develop effective long-term management of weight by targeting 5-HT2CR desensitization.SIGNIFICANCE STATEMENT:By demonstrating that the combination of barbadin with a GPCR agonist can provide prolonged weight-lowering benefits in a preclinical setting, our work should call for additional efforts to validate barbadin as a safe and effective medicine or to use barbadin as a lead compound to develop more suitable compounds for obesity treatment.	lorcaserin	151-161	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	55-62
34031163-7	2021	These results prove the concept that inhibition of 5-HT2CR desensitization can be a valid strategy to improve the long-term weight loss effects of lorcaserin or other 5-HT2CR agonists.	lorcaserin	147-157	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	51-58
33928736-2	2021	Lorcaserin, a 5-HT2C receptor agonist, attenuates drug self-administration in animal models.	lorcaserin	0-10	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	14-29
34130255-1	2021	Recent preclinical and clinical studies suggest that lorcaserin, a preferential serotonin 2C receptor (5-HT2CR) agonist that was approved for the treatment of obesity, possesses antiepileptic properties.	lorcaserin	53-63	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	80-110
34130255-12	2021	If mice were treated with the selective 5-HT2CR antagonist SB 242084 (0.5 or 1 mg/kg) plus lorcaserin (3 mg/kg), a significantly increased HTR was observed, relative to vehicle (P = 0.01 and P = 0.03), however, the HTR was much lower than what was elicited by DOI or DOI plus lorcaserin.	lorcaserin	91-101	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	40-47
35094259-1	2022	Lorcaserin, a selective serotonin 5-HT2C receptor agonist, was developed as an appetite suppressant with the rationale of minimizing the risk of cardiovascular toxicity associated with non-selective serotoninergic agents such as fenfluramine.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Homo sapiens	24-49
34031163-0	2021	Barbadin potentiates long-term effects of lorcaserin on POMC neurons and weight loss.	lorcaserin	42-52	proopiomelanocortin	Homo sapiens	56-60
33909316-4	2021	The serotonin 2C receptor (5-HT2C R) is the primary receptor through which 5-HT impacts feeding and body weight and 5-HT2C R agonist lorcaserin was released for obesity treatment in 2012.	lorcaserin	133-143	5-hydroxytryptamine receptor 2C	Homo sapiens	27-33
33467149-5	2021	Analyses of brain slices from nicotine-withdrawn animals revealed that lorcaserin treatment recovered the reduced number of doublecortin (DCX)-positive cells, but it did not affect the number of Ki-67- or 5-bromo-2"-deoxyuridine (BrdU)-positive cells or the maturation of proliferating neurons in drug-weaned rats.	lorcaserin	71-81	doublecortin	Rattus norvegicus	124-136
33467149-5	2021	Analyses of brain slices from nicotine-withdrawn animals revealed that lorcaserin treatment recovered the reduced number of doublecortin (DCX)-positive cells, but it did not affect the number of Ki-67- or 5-bromo-2"-deoxyuridine (BrdU)-positive cells or the maturation of proliferating neurons in drug-weaned rats.	lorcaserin	71-81	doublecortin	Rattus norvegicus	138-141
32234370-0	2020	Lorcaserin Administration has Pro-Ejaculatory Effects in Rats via 5-HT2C Receptors Activation: A Putative Pharmacologic Strategy to Delayed Ejaculation?	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Rattus norvegicus	66-72
32642780-1	2020	Lorcaserin (LOR) is selective and potent antiobesity drug that targets the activation of the serotonin 5HT2C receptor.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Homo sapiens	93-117
32642780-1	2020	Lorcaserin (LOR) is selective and potent antiobesity drug that targets the activation of the serotonin 5HT2C receptor.	lorcaserin	12-15	5-hydroxytryptamine receptor 2C	Homo sapiens	93-117
32234370-1	2020	BACKGROUND: Lorcaserin is an anti-obesity drug whose weight loss effect results from 5-hydroxytryptamin (5-HT)2C receptors activation.	lorcaserin	12-22	5-hydroxytryptamine receptor 2C	Rattus norvegicus	105-112
32234370-8	2020	On the other hand, lorcaserin administration (0.3-1.0 mg/kg, intravenous) induced ejaculation in anesthetized rats, which was prevented by the 5-HT2C-selective antagonist SB 242084 (0.1 and 0.3 mg/kg, intravenous).	lorcaserin	19-29	5-hydroxytryptamine receptor 2C	Rattus norvegicus	143-149
32234370-15	2020	CONCLUSION: Our results demonstrate that the clinically approved 5-HT2C agonist lorcaserin is a strong facilitator of ejaculation in rats.	lorcaserin	80-90	5-hydroxytryptamine receptor 2C	Rattus norvegicus	65-71
32234370-17	2020	Lorcaserin Administration has Pro-Ejaculatory Effects in Rats via 5-HT2C Receptors Activation: A Putative Pharmacologic Strategy to Delayed Ejaculation?	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Rattus norvegicus	66-72
31987863-2	2020	Lorcaserin is a serotonin 5-HT2C receptor (5-HT2CR) agonist that has recently been reported to reduce abuse-related effects of the opioid analgesic oxycodone.	lorcaserin	0-10	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	43-50
31880085-10	2020	Moreover, we identified that 95% 5-HT2c receptors were colocalized with NPY positive neurons, and increased Arc NPY mRNA expression induced by risperidone was markedly reduced by cotreatment with lorcaserin, a specific 5-HT2c receptor agonist.	lorcaserin	196-206	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	33-39
31880085-10	2020	Moreover, we identified that 95% 5-HT2c receptors were colocalized with NPY positive neurons, and increased Arc NPY mRNA expression induced by risperidone was markedly reduced by cotreatment with lorcaserin, a specific 5-HT2c receptor agonist.	lorcaserin	196-206	neuropeptide Y	Mus musculus	72-75
31880085-10	2020	Moreover, we identified that 95% 5-HT2c receptors were colocalized with NPY positive neurons, and increased Arc NPY mRNA expression induced by risperidone was markedly reduced by cotreatment with lorcaserin, a specific 5-HT2c receptor agonist.	lorcaserin	196-206	neuropeptide Y	Mus musculus	112-115
31880085-10	2020	Moreover, we identified that 95% 5-HT2c receptors were colocalized with NPY positive neurons, and increased Arc NPY mRNA expression induced by risperidone was markedly reduced by cotreatment with lorcaserin, a specific 5-HT2c receptor agonist.	lorcaserin	196-206	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	33-48
31987863-12	2020	Together, these data indicate that lorcaserin-mediated activation of the 5-HT2CR may represent a new pharmacological approach to augment opioid-induced antinociception.	lorcaserin	35-45	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	73-80
32079105-4	2020	Lorcaserin, an appetite control drug, has demonstrated efficacy in appetite control by targeting 5-HT2C but causes undesirable side effects.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Homo sapiens	97-103
31544267-7	2020	Compared with placebo, lorcaserin not only reduced weight, BMI and waist circumference but also improved SBP, DBP, heart rate, LDL, triglycerides, fasting plasma glucose and HbA1c.	lorcaserin	23-33	selenium binding protein 1	Homo sapiens	105-108
31544267-7	2020	Compared with placebo, lorcaserin not only reduced weight, BMI and waist circumference but also improved SBP, DBP, heart rate, LDL, triglycerides, fasting plasma glucose and HbA1c.	lorcaserin	23-33	D-box binding PAR bZIP transcription factor	Homo sapiens	110-113
30961494-0	2020	Chemistry, Analysis, Pharmacokinetics and Pharmacodynamics aspects of Lorcaserin, a selective serotonin 5-HT2C receptor agonist: An update.	lorcaserin	70-80	5-hydroxytryptamine receptor 2C	Homo sapiens	94-119
30622024-7	2019	Similar effect of compound 58 was observed with synthetic orthosteric agonist lorcaserin on 5-HT2B.	lorcaserin	78-88	5-hydroxytryptamine receptor 2B	Rattus norvegicus	92-98
31127052-6	2019	Consistent with this, loss of the BBSome reduced cell surface expression of the 5-HT2CR, interfered with serotonin-evoked increase in intracellular calcium and membrane potential, and blunted the anorectic and weight-reducing responses evoked by the 5-HT2cR agonist, lorcaserin.	lorcaserin	267-277	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	80-87
30689993-2	2019	For example, activation of serotonin 5-HT2C GPCRs is pharmacotherapeutic for obesity, but there is tolerance to the anorectic effect of the only approved 5-HT2C agonist, lorcaserin.	lorcaserin	170-180	5-hydroxytryptamine receptor 2C	Homo sapiens	37-43
30689993-2	2019	For example, activation of serotonin 5-HT2C GPCRs is pharmacotherapeutic for obesity, but there is tolerance to the anorectic effect of the only approved 5-HT2C agonist, lorcaserin.	lorcaserin	170-180	5-hydroxytryptamine receptor 2C	Homo sapiens	154-160
30689993-4	2019	Lorcaserin, which displays potency and efficacy equal to 5-HT, desensitized the 5-HT2C receptor significantly more than 5-HT (p<0.05).	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Homo sapiens	80-86
31019729-4	2019	Methods: This post hoc analysis evaluated the magnitude of weight loss in adults across age quartiles with lorcaserin, a serotonin (5-HT) 2C receptor agonist indicated as an adjunct to a reduced-caloric diet and increased physical activity for chronic weight management.	lorcaserin	107-117	5-hydroxytryptamine receptor 2C	Homo sapiens	121-149
31774584-0	2019	5-HT2c agonist, lorcaserin, reduces aggressive responding in intermittent explosive disorder: A pilot study.	lorcaserin	16-26	5-hydroxytryptamine receptor 2C	Homo sapiens	0-6
31774584-3	2019	OBJECTIVES: To test the hypothesis that pretreatment with the selective 5-HT2c agonist, lorcaserin, can reduce aggressive responding in impulsively aggressive individuals.	lorcaserin	88-98	5-hydroxytryptamine receptor 2C	Homo sapiens	72-78
31581577-5	2019	Due to limited drug options available and considering the adverse drug effects of Lorcaserin, the development of new drugs which are highly specific toward the 5HT2C target and with lesser side effects is essential.	lorcaserin	82-92	5-hydroxytryptamine receptor 2C	Homo sapiens	160-165
31087031-9	2019	These data have implications for our understanding of the aetiology of PWS-related behavioural traits and translational relevance for individuals with PWS who may seek to control appetite with the new obesity treatment 5-HT2CR agonist lorcaserin.	lorcaserin	235-245	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	219-226
30929417-4	2019	Lorcaserin stimulates proopiomelanocortin (POMC)/cocaine- and amphetamine-regulated transcript (CART) neurons and inhibits neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurons, which results in the activation of melanocortin 3/4 receptors.	lorcaserin	0-10	proopiomelanocortin	Homo sapiens	22-41
30929417-4	2019	Lorcaserin stimulates proopiomelanocortin (POMC)/cocaine- and amphetamine-regulated transcript (CART) neurons and inhibits neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurons, which results in the activation of melanocortin 3/4 receptors.	lorcaserin	0-10	proopiomelanocortin	Homo sapiens	43-47
30929417-4	2019	Lorcaserin stimulates proopiomelanocortin (POMC)/cocaine- and amphetamine-regulated transcript (CART) neurons and inhibits neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurons, which results in the activation of melanocortin 3/4 receptors.	lorcaserin	0-10	neuropeptide Y	Homo sapiens	123-137
30929417-4	2019	Lorcaserin stimulates proopiomelanocortin (POMC)/cocaine- and amphetamine-regulated transcript (CART) neurons and inhibits neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurons, which results in the activation of melanocortin 3/4 receptors.	lorcaserin	0-10	neuropeptide Y	Homo sapiens	139-142
30929417-4	2019	Lorcaserin stimulates proopiomelanocortin (POMC)/cocaine- and amphetamine-regulated transcript (CART) neurons and inhibits neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurons, which results in the activation of melanocortin 3/4 receptors.	lorcaserin	0-10	agouti related neuropeptide	Homo sapiens	168-172
30293771-18	2018	In patients with diabetes, lorcaserin resulted in a reduction of 0 33% (95% CI 0 29-0 38; p<0 0001) in HbA1c compared with placebo at 1 year from a mean baseline of 53 mmol/mol (7 0%).	lorcaserin	27-37	hemoglobin subunit alpha 1	Homo sapiens	106-110
30419272-0	2019	Persistent attenuation of nicotine self-administration in rats by co-administration of chronic nicotine infusion with the dopamine D1 receptor antagonist SCH-23390 or the serotonin 5-HT2C agonist lorcaserin.	lorcaserin	196-206	5-hydroxytryptamine receptor 2C	Rattus norvegicus	181-187
30523523-6	2019	Preclinical models suggest that nociceptin receptor antagonists, the selective serotonin 5-HT2C receptor agonist lorcaserin, monoamine stabilizers, and selective orexin-1 receptor antagonists might be helpful.	lorcaserin	113-123	5-hydroxytryptamine receptor 2C	Homo sapiens	79-104
30233224-4	2018	Lorcaserin is thought to reduce weight by targeting the serotonin (5HT2c) system to induce satiety.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Homo sapiens	67-72
30282043-3	2018	(2018) demonstrate that a small and often overlooked population of POMC neurons in the brainstem contributes to satiation induced by the FDA-approved drug lorcaserin.	lorcaserin	155-165	proopiomelanocortin	Homo sapiens	67-71
30574343-6	2018	Results: According to this mediation analysis, lorcaserin 10 mg BID improved a spectrum of adiposopathic metabolic abnormalities with varying contributions attributable to weight loss.	lorcaserin	47-57	BH3 interacting domain death agonist	Homo sapiens	64-67
30574343-9	2018	Conclusions: Across Phase III clinical trials, lorcaserin 10 mg BID improved multiple cardiometabolic parameters through both weight-loss dependent and independent mechanisms.	lorcaserin	47-57	BH3 interacting domain death agonist	Homo sapiens	64-67
29217539-0	2018	Inhibition of Cocaine and 3,4-Methylenedioxypyrovalerone (MDPV) Self-Administration by Lorcaserin Is Mediated by 5-HT2C Receptors in Rats.	lorcaserin	87-97	5-hydroxytryptamine receptor 2C	Homo sapiens	113-119
29217539-1	2018	Lorcaserin is a serotonin (5-HT)2C receptor-preferring agonist approved by the US Food and Drug Administration to treat obesity.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Homo sapiens	16-43
29217539-3	2018	Although this effect is partially inhibited by a 5-HT2C receptor antagonist (SB242084), lorcaserin also has effects at 5-HT2A and 5-HT1A receptors, and the relative contribution of these receptors to its anti-cocaine effects has not been investigated.	lorcaserin	88-98	5-hydroxytryptamine receptor 2A	Homo sapiens	119-125
29217539-3	2018	Although this effect is partially inhibited by a 5-HT2C receptor antagonist (SB242084), lorcaserin also has effects at 5-HT2A and 5-HT1A receptors, and the relative contribution of these receptors to its anti-cocaine effects has not been investigated.	lorcaserin	88-98	5-hydroxytryptamine receptor 1A	Homo sapiens	130-136
28805659-6	2017	Finally, we showed that treatment with the HTR2C-specific agonist lorcaserin suppressed olanzapine-induced hyperphagia and weight gain.	lorcaserin	66-76	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	43-48
29217539-9	2018	Antagonism of 5-HT2C (but not 5-HT1A or 5-HT2A) receptors blocked the effects of lorcaserin on cocaine and MDPV self-administration.	lorcaserin	81-91	5-hydroxytryptamine receptor 2C	Homo sapiens	14-20
29217539-10	2018	Taken together, these data provide additional support for further development of 5-HT2C receptor agonists, such as lorcaserin, for the treatment of stimulant abuse.	lorcaserin	115-125	5-hydroxytryptamine receptor 2C	Homo sapiens	81-87
29040827-1	2017	BACKGROUND: Accumulating evidence suggests that the FDA-approved serotonin 5-HT2C receptor agonist, lorcaserin (Belviq ), may be a promising candidate for the management of substance use disorders, including nicotine addiction.	lorcaserin	100-110	5-hydroxytryptamine receptor 2C	Homo sapiens	65-90
29031711-6	2017	Examining the mechanism of this effect, we reveal a necessary and sufficient neurochemical mediator of lorcaserin"s glucoregulatory effects, brain pro-opiomelanocortin (POMC) peptides.	lorcaserin	103-113	pro-opiomelanocortin-alpha	Mus musculus	147-167
29031711-6	2017	Examining the mechanism of this effect, we reveal a necessary and sufficient neurochemical mediator of lorcaserin"s glucoregulatory effects, brain pro-opiomelanocortin (POMC) peptides.	lorcaserin	103-113	pro-opiomelanocortin-alpha	Mus musculus	169-173
29031711-7	2017	To clarify further lorcaserin"s therapeutic brain circuit, we examined the receptor target of POMC peptides.	lorcaserin	19-29	pro-opiomelanocortin-alpha	Mus musculus	94-98
28294132-8	2017	Somewhat similar effects were observed with lorcaserin, a 5-HT2C agonist with potent 5-HT2B and 5-HT2A agonist activities, which is approved for treating obesity.	lorcaserin	44-54	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	58-64
28294132-8	2017	Somewhat similar effects were observed with lorcaserin, a 5-HT2C agonist with potent 5-HT2B and 5-HT2A agonist activities, which is approved for treating obesity.	lorcaserin	44-54	5-hydroxytryptamine (serotonin) receptor 2B	Mus musculus	85-97
28099839-5	2017	We also demonstrate that the Ht2Cr agonist lorcaserin-induced improvements in glucose and insulin tolerance are blocked by TrpC5 deficiency in Pomc neurons.	lorcaserin	43-53	transient receptor potential cation channel subfamily C member 5	Homo sapiens	123-128
28338324-0	2017	Studies To Examine Potential Tolerability Differences between the 5-HT2C Receptor Selective Agonists Lorcaserin and CP-809101.	lorcaserin	101-111	5-hydroxytryptamine receptor 2C	Rattus norvegicus	66-72
28338324-1	2017	Lorcaserin (LOR) is a selective 5-HT2C receptor agonist that has been FDA approved as a treatment for obesity.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Rattus norvegicus	32-38
28338324-1	2017	Lorcaserin (LOR) is a selective 5-HT2C receptor agonist that has been FDA approved as a treatment for obesity.	lorcaserin	12-15	5-hydroxytryptamine receptor 2C	Rattus norvegicus	32-38
27516377-4	2017	Notably, 5-HT medications, including fluoxetine, d-fenfluramine, and lorcaserin (a selective 5-HT2CR agonist), act on 5-HT2CRs expressed by DA neurons to inhibit binge-like eating in mice.	lorcaserin	69-79	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	93-100
28099839-5	2017	We also demonstrate that the Ht2Cr agonist lorcaserin-induced improvements in glucose and insulin tolerance are blocked by TrpC5 deficiency in Pomc neurons.	lorcaserin	43-53	proopiomelanocortin	Homo sapiens	143-147
27241709-0	2016	Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Rattus norvegicus	167-173
27931246-8	2016	Furthermore, these findings have translational relevance for individuals with PWS who may seek to control appetite with another 5-HT2CR agonist, the new obesity treatment lorcaserin.	lorcaserin	171-181	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	128-135
27085605-7	2016	The 5-HT2C agonists lorcaserin and CP-809,101 dose-dependently suppressed ASs, an effect blocked by the selective 5-HT2C antagonist SB 242984.	lorcaserin	20-30	5-hydroxytryptamine receptor 2C	Rattus norvegicus	4-10
27085605-7	2016	The 5-HT2C agonists lorcaserin and CP-809,101 dose-dependently suppressed ASs, an effect blocked by the selective 5-HT2C antagonist SB 242984.	lorcaserin	20-30	5-hydroxytryptamine receptor 2C	Rattus norvegicus	114-120
27241709-1	2016	RATIONALE: The 5-HT2C receptor agonist lorcaserin (Belviq ) has been approved by the FDA for the treatment of obesity.	lorcaserin	39-49	5-hydroxytryptamine receptor 2C	Rattus norvegicus	15-21
27241709-1	2016	RATIONALE: The 5-HT2C receptor agonist lorcaserin (Belviq ) has been approved by the FDA for the treatment of obesity.	lorcaserin	51-57	5-hydroxytryptamine receptor 2C	Rattus norvegicus	15-21
27241709-5	2016	RESULTS: Lorcaserin (0.3-0.6 mg/kg SC) and CP-809101 (0.6-1 mg/kg SC) reduced premature responding in rats trained on the 5-CSRTT and improved accuracy in a Go-NoGo task by reducing false alarms.	lorcaserin	9-19	reticulon 4	Rattus norvegicus	160-164
27116910-1	2016	OBJECTIVES: Lorcaserin is a selective 5-HT2C (5-hydroxytryptamine 2C) receptor agonist indicated for weight management.	lorcaserin	12-22	5-hydroxytryptamine receptor 2C	Homo sapiens	38-44
27206567-3	2016	The potency of lorcaserin for the 5-HT2C receptor is 14-fold greater than its potency for the 5-HT2A receptor and 61-fold greater than its potency for the 5-HT2B receptor.	lorcaserin	15-25	5-hydroxytryptamine receptor 2A	Homo sapiens	94-109
27206567-3	2016	The potency of lorcaserin for the 5-HT2C receptor is 14-fold greater than its potency for the 5-HT2A receptor and 61-fold greater than its potency for the 5-HT2B receptor.	lorcaserin	15-25	5-hydroxytryptamine receptor 2B	Homo sapiens	155-170
26384326-4	2015	The 5-HT2C receptor selective agonist 1-(3-chlorophenyl)piperazine (mCPP, 0.032-1.0 mg/kg) and lorcaserin induced yawning which was attenuated by the 5-HT2C receptor selective antagonist 6-chloro-5-methyl-N-(6-[(2-methylpyridin-3-yl)oxy]pydidin-3-yl)indoline-1-carboxamide (1.0 mg/kg).	lorcaserin	95-105	5-hydroxytryptamine receptor 2C	Rattus norvegicus	150-156
26375926-4	2015	The present study examined the effect of a selective 5-HT2CR agonist lorcaserin on behavioral sensitization and naloxone-precipitated withdrawal symptoms in heroin-treated mice.	lorcaserin	69-79	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	53-60
26384326-7	2015	At larger doses, lorcaserin produced forepaw treading, which was attenuated by the 5-HT1A receptor selective antagonist N-(2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl)-N-(2-pyridyl)cyclohexanecarboxamide (0.178 mg/kg).	lorcaserin	17-27	5-hydroxytryptamine receptor 1A	Rattus norvegicus	83-89
26384326-8	2015	While the behavioral effects of lorcaserin in rats are consistent with it having agonist activity at 5-HT2C receptors, these data suggest that at larger doses it also has agonist activity at 5-HT2A and possibly 5-HT1A receptors.	lorcaserin	32-42	5-hydroxytryptamine receptor 2C	Rattus norvegicus	101-107
25727097-10	2015	In contrast, the specific 5-HT2C receptor agonist lorcaserin, recently approved for the treatment of obesity, attenuates ghrelin-induced food intake.	lorcaserin	50-60	5-hydroxytryptamine receptor 2C	Rattus norvegicus	26-32
25727097-10	2015	In contrast, the specific 5-HT2C receptor agonist lorcaserin, recently approved for the treatment of obesity, attenuates ghrelin-induced food intake.	lorcaserin	50-60	ghrelin and obestatin prepropeptide	Rattus norvegicus	121-128
25109272-2	2014	The purpose of this study was to evaluate the efficacy of a novel 5-HT2c receptor agonist, lorcaserin for reducing alcohol consumption in alcohol-preferring (P) rats.	lorcaserin	91-101	5-hydroxytryptamine receptor 2C	Rattus norvegicus	66-72
24953434-9	2014	The 5HT2C agonist lorcaserin significantly decreased nicotine self-administration in the licking paradigm at the same dose threshold as with lever press responding.	lorcaserin	18-28	5-hydroxytryptamine receptor 2C	Rattus norvegicus	4-9
25109272-11	2014	These results show the efficacy of lorcaserin in reducing alcohol intake without a significant effect on water intake and locomotion suggesting the involvement of 5-HT2c receptors in alcohol seeking behavior.	lorcaserin	35-45	5-hydroxytryptamine receptor 2C	Rattus norvegicus	163-169
24935789-4	2014	RESULTS: The 5-HT2C agonists mCPP (1 mg/kg, i.p) and lorcaserin (3 mg/kg, i.p), but not RO60-0175 (1-3 mg/kg i.p.	lorcaserin	53-63	5-hydroxytryptamine receptor 2C	Rattus norvegicus	13-19
24064009-5	2014	Lorcaserin, a 5HT2C agonist has moderate efficacy with an acceptable safety profile.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Homo sapiens	14-19
24935789-8	2014	CONCLUSIONS: In our animal model of TLE, mCPP and lorcaserin were anticonvulsant; likely acting on receptor subtypes other than 5-HT2C.	lorcaserin	50-60	5-hydroxytryptamine receptor 2C	Rattus norvegicus	128-134
24041919-1	2013	The recent US Food and Drug Administration (FDA) approval of the serotonin (5-hydroxytryptamine, 5-HT) 5-HT2C receptor agonist lorcaserin for the treatment of obesity represents a new therapeutic drug class available to the clinic.	lorcaserin	127-137	5-hydroxytryptamine receptor 2C	Homo sapiens	103-109
24292660-6	2013	This review provides an overview of 5-HT receptor pharmacology and discusses two recent 5-HT receptor subtype-selective drugs, lorcaserin and pimavanserin, which target the 5HT2C and 5HT2A receptors and provide new treatments for obesity and Parkinson"s disease psychosis, respectively.	lorcaserin	127-137	5-hydroxytryptamine receptor 2C	Homo sapiens	173-178
24273398-0	2013	Lorcaserin (Belviq): A Selective Serotonin 5-HT2C Agonist In the Treatment of Obesity.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Homo sapiens	43-49
23661689-1	2013	BACKGROUND: Lorcaserin is a selective 5-HT2C agonist evaluated for weight management in clinical trials.	lorcaserin	12-22	5-hydroxytryptamine receptor 2C	Homo sapiens	38-44
23800750-10	2013	Lorcaserin is a selective serotonin 5-HT2C agonist that regulates food intake, while the combination of phentermine/topiramate causes appetite suppression and enhanced satiety.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Homo sapiens	36-42
23184281-1	2013	RATIONALE: Selective 5-HT2C receptor agonists, such as lorcaserin, are being developed for the treatment of obesity.	lorcaserin	55-65	5-hydroxytryptamine receptor 2C	Rattus norvegicus	21-27
23184281-10	2013	Finally, there may be differences in the side effect profiles between lorcaserin and CP-809101, raising the possibility for tolerability differences amongst 5-HT2C agonists.	lorcaserin	70-80	5-hydroxytryptamine receptor 2C	Homo sapiens	157-163
22266842-0	2012	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist.	lorcaserin	114-124	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
22259019-6	2012	With recombinant UGT enzymes, lorcaserin N-carbamoyl glucuronidation was predominantly catalyzed by three UGT2Bs (UGT2B7, UGT2B15, and UGT2B17), whereas two UGT1As (UGT1A6 and UGT1A9) played a minor role.	lorcaserin	30-40	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	114-120
23529825-1	2013	Oral lorcaserin (BELVIQ( )), a selective serotonin 5-HT2C receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes).	lorcaserin	5-15	5-hydroxytryptamine receptor 2C	Homo sapiens	41-66
23529825-1	2013	Oral lorcaserin (BELVIQ( )), a selective serotonin 5-HT2C receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes).	lorcaserin	17-23	5-hydroxytryptamine receptor 2C	Homo sapiens	41-66
22421927-10	2012	More patients lost >=5% body weight with lorcaserin BID (37.5%; P < 0.001) or lorcaserin QD (44.7%; P < 0.001) vs. placebo (16.1%; modified intent to treat (MITT)/last observation carried forward (LOCF)).	lorcaserin	44-54	BH3 interacting domain death agonist	Homo sapiens	55-58
22266842-2	2012	The oxidative metabolism of lorcaserin, mediated by recombinant human cytochrome P450 (P450) and flavin-containing monooxygenase (FMO) enzymes, was examined in vitro to identify the enzymes involved in the generation of its primary oxidative metabolites, N-hydroxylorcaserin, 7-hydroxylorcaserin, 5-hydroxylorcaserin, and 1-hydroxylorcaserin.	lorcaserin	28-38	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	70-92
22259019-6	2012	With recombinant UGT enzymes, lorcaserin N-carbamoyl glucuronidation was predominantly catalyzed by three UGT2Bs (UGT2B7, UGT2B15, and UGT2B17), whereas two UGT1As (UGT1A6 and UGT1A9) played a minor role.	lorcaserin	30-40	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	122-129
21795446-9	2011	RESULTS: Significantly more patients treated with lorcaserin 10 mg BID and QD lost at least 5% of baseline body weight (47.2 and 40.2%, respectively) as compared with placebo (25.0%, P < 0.001 vs. lorcaserin BID).	lorcaserin	50-60	BH3 interacting domain death agonist	Homo sapiens	67-70
22259019-6	2012	With recombinant UGT enzymes, lorcaserin N-carbamoyl glucuronidation was predominantly catalyzed by three UGT2Bs (UGT2B7, UGT2B15, and UGT2B17), whereas two UGT1As (UGT1A6 and UGT1A9) played a minor role.	lorcaserin	30-40	UDP glucuronosyltransferase family 2 member B17	Homo sapiens	135-142
22259019-6	2012	With recombinant UGT enzymes, lorcaserin N-carbamoyl glucuronidation was predominantly catalyzed by three UGT2Bs (UGT2B7, UGT2B15, and UGT2B17), whereas two UGT1As (UGT1A6 and UGT1A9) played a minor role.	lorcaserin	30-40	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	165-171
22259019-6	2012	With recombinant UGT enzymes, lorcaserin N-carbamoyl glucuronidation was predominantly catalyzed by three UGT2Bs (UGT2B7, UGT2B15, and UGT2B17), whereas two UGT1As (UGT1A6 and UGT1A9) played a minor role.	lorcaserin	30-40	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	176-182
22259019-8	2012	The rank order of catalytic efficiency of human UGT enzymes for lorcaserin N-carbamoyl glucuronidation was UGT2B15 > UGT2B7 > UGT2B17 > UGT1A9 > UGT1A6.	lorcaserin	64-74	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	107-114
22259019-8	2012	The rank order of catalytic efficiency of human UGT enzymes for lorcaserin N-carbamoyl glucuronidation was UGT2B15 > UGT2B7 > UGT2B17 > UGT1A9 > UGT1A6.	lorcaserin	64-74	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	120-126
22259019-8	2012	The rank order of catalytic efficiency of human UGT enzymes for lorcaserin N-carbamoyl glucuronidation was UGT2B15 > UGT2B7 > UGT2B17 > UGT1A9 > UGT1A6.	lorcaserin	64-74	UDP glucuronosyltransferase family 2 member B17	Homo sapiens	132-139
22259019-8	2012	The rank order of catalytic efficiency of human UGT enzymes for lorcaserin N-carbamoyl glucuronidation was UGT2B15 > UGT2B7 > UGT2B17 > UGT1A9 > UGT1A6.	lorcaserin	64-74	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	145-151
22259019-8	2012	The rank order of catalytic efficiency of human UGT enzymes for lorcaserin N-carbamoyl glucuronidation was UGT2B15 > UGT2B7 > UGT2B17 > UGT1A9 > UGT1A6.	lorcaserin	64-74	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	157-163
22259019-9	2012	Inhibition of lorcaserin N-carbamoyl glucuronidation activities of UGT2B7, UGT2B15, and UGT2B17 in human liver microsomes by mefenamic acid, bisphenol A, and eugenol further substantiated the involvement of these UGT2B isoforms.	lorcaserin	14-24	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	67-73
22259019-9	2012	Inhibition of lorcaserin N-carbamoyl glucuronidation activities of UGT2B7, UGT2B15, and UGT2B17 in human liver microsomes by mefenamic acid, bisphenol A, and eugenol further substantiated the involvement of these UGT2B isoforms.	lorcaserin	14-24	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	75-82
22259019-9	2012	Inhibition of lorcaserin N-carbamoyl glucuronidation activities of UGT2B7, UGT2B15, and UGT2B17 in human liver microsomes by mefenamic acid, bisphenol A, and eugenol further substantiated the involvement of these UGT2B isoforms.	lorcaserin	14-24	UDP glucuronosyltransferase family 2 member B17	Homo sapiens	88-95
22266842-4	2012	In 16 individual human liver microsomal preparations (HLM), formation of N-hydroxylorcaserin was correlated with CYP2B6, 7-hydroxylorcaserin was correlated with CYP2D6, 5-hydroxylorcaserin was correlated with CYP1A2 and CYP3A4, and 1-hydroxylorcaserin was correlated with CYP3A4 activity at 10.0 muM lorcaserin.	lorcaserin	82-92	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	113-119
22266842-10	2012	Multiple human P450 and FMO enzymes catalyze the formation of four primary oxidative metabolites of lorcaserin, suggesting that lorcaserin has a low probability of drug-drug interactions by concomitant medications.	lorcaserin	100-110	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	15-27
22266842-10	2012	Multiple human P450 and FMO enzymes catalyze the formation of four primary oxidative metabolites of lorcaserin, suggesting that lorcaserin has a low probability of drug-drug interactions by concomitant medications.	lorcaserin	128-138	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	15-27
22085383-7	2011	The serotonin 5-HT(2C)-receptor selective agonist lorcaserin, a drug specifically developed to target satiety without producing the side effect profiles of its predecessors, has been shown to significantly reduce energy intake and body weight.	lorcaserin	50-60	5-hydroxytryptamine receptor 2C	Homo sapiens	4-31
21795446-9	2011	RESULTS: Significantly more patients treated with lorcaserin 10 mg BID and QD lost at least 5% of baseline body weight (47.2 and 40.2%, respectively) as compared with placebo (25.0%, P < 0.001 vs. lorcaserin BID).	lorcaserin	50-60	BH3 interacting domain death agonist	Homo sapiens	211-214
21795446-10	2011	Least squares mean (95% confidence interval) weight loss with lorcaserin BID and QD was 5.8% (5.5-6.2%) and 4.7% (4.3-5.2%), respectively, compared with 2.8% (2.5-3.2%) with placebo (P < 0.001 vs. lorcaserin BID; least squares mean difference, 3.0%).	lorcaserin	62-72	BH3 interacting domain death agonist	Homo sapiens	73-76
21795446-10	2011	Least squares mean (95% confidence interval) weight loss with lorcaserin BID and QD was 5.8% (5.5-6.2%) and 4.7% (4.3-5.2%), respectively, compared with 2.8% (2.5-3.2%) with placebo (P < 0.001 vs. lorcaserin BID; least squares mean difference, 3.0%).	lorcaserin	62-72	BH3 interacting domain death agonist	Homo sapiens	211-214
21795446-11	2011	Weight loss of at least 10% was achieved by 22.6 and 17.4% of patients receiving lorcaserin 10 mg BID and QD, respectively, and 9.7% of patients in the placebo group (P < 0.001 vs. lorcaserin BID).	lorcaserin	81-91	BH3 interacting domain death agonist	Homo sapiens	98-101
21795446-13	2011	U.S. Food and Drug Administration-defined echocardiographic valvulopathy occurred in 2.0% of patients on placebo and 2.0% on lorcaserin 10 mg BID.	lorcaserin	125-135	BH3 interacting domain death agonist	Homo sapiens	142-145
19900026-0	2009	Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for "sick fat" and metabolic disease.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Homo sapiens	29-35
21636655-0	2011	Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Rattus norvegicus	14-20
21181547-6	2011	A number of new preparations, including combinations of the existing drugs topiramate plus phentermine, bupropion plus naltrexone, and the selective 5-HT(2C) agonist lorcaserin have recently been filed for approval.	lorcaserin	166-176	5-hydroxytryptamine receptor 2C	Homo sapiens	149-156
19900026-3	2009	Lorcaserin (APD-356) is a selective 5-HT2c receptor agonist that promotes weight loss.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Homo sapiens	36-42
19900026-3	2009	Lorcaserin (APD-356) is a selective 5-HT2c receptor agonist that promotes weight loss.	lorcaserin	12-19	5-hydroxytryptamine receptor 2C	Homo sapiens	36-42
18252809-2	2008	In this study, we describe the in vitro and in vivo characteristics of lorcaserin [(1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3 benzazepine], a selective, high affinity 5-HT(2C) full agonist.	lorcaserin	71-81	5-hydroxytryptamine receptor 2C	Homo sapiens	171-178
18095642-0	2008	Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.	lorcaserin	49-107	5-hydroxytryptamine receptor 2C	Rattus norvegicus	144-150
18095642-0	2008	Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.	lorcaserin	109-119	5-hydroxytryptamine receptor 2C	Rattus norvegicus	144-150
18095642-2	2008	Compound 7d (lorcaserin, APD356) was identified as one of the more potent and selective compounds in vitro (pEC50 values in functional assays measuring [(3)H]phosphoinositol turnover: 5-HT2C = 8.1; 5-HT2A = 6.8; 5-HT2B = 6.1) and was potent in an acute in vivo rat food intake model upon oral administration (ED50 at 6 h = 18 mg/kg).	lorcaserin	13-23	5-hydroxytryptamine receptor 2C	Rattus norvegicus	184-190
18095642-2	2008	Compound 7d (lorcaserin, APD356) was identified as one of the more potent and selective compounds in vitro (pEC50 values in functional assays measuring [(3)H]phosphoinositol turnover: 5-HT2C = 8.1; 5-HT2A = 6.8; 5-HT2B = 6.1) and was potent in an acute in vivo rat food intake model upon oral administration (ED50 at 6 h = 18 mg/kg).	lorcaserin	25-31	5-hydroxytryptamine receptor 2C	Rattus norvegicus	184-190
18252809-3	2008	Lorcaserin bound to human and rat 5-HT(2C) receptors with high affinity (K(i) = 15 +/- 1 nM, 29 +/- 7 nM, respectively), and it was a full agonist for the human 5-HT(2C) receptor in a functional inositol phosphate accumulation assay, with 18- and 104-fold selectivity over 5-HT(2A) and 5-HT(2B) receptors, respectively.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Homo sapiens	34-41
18252809-3	2008	Lorcaserin bound to human and rat 5-HT(2C) receptors with high affinity (K(i) = 15 +/- 1 nM, 29 +/- 7 nM, respectively), and it was a full agonist for the human 5-HT(2C) receptor in a functional inositol phosphate accumulation assay, with 18- and 104-fold selectivity over 5-HT(2A) and 5-HT(2B) receptors, respectively.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Homo sapiens	161-168
18252809-4	2008	Lorcaserin was also highly selective for human 5-HT(2C) over other human 5-HT receptors (5-HT(1A), 5-HT(3), 5-HT(4C), 5-HT5(5A), 5-HT(6), and 5-HT(7)), in addition to a panel of 67 other G protein-coupled receptors and ion channels.	lorcaserin	0-10	5-hydroxytryptamine receptor 2C	Homo sapiens	47-54
18252809-10	2008	These data demonstrate lorcaserin to be a potent, selective, and efficacious agonist of the 5-HT(2C) receptor, with potential for the treatment of obesity.	lorcaserin	23-33	5-hydroxytryptamine receptor 2C	Homo sapiens	92-99